W3 · DCL0030

Formulation & Performance

Formulation & In Vivo Data

Product-specific storage, solubility, purity, availability and lead time require confirmation. For research use only. DC Chemicals supplies the lipid only; literature LNP performance is not guaranteed.

pKa and N/P

The complete main article was unavailable. No pKa value, intrinsic/apparent/LNP-apparent type, measurement method or conditions were identified in the supplied SI or abstract. N/P, lipid:RNA mass ratio and their definitions also remain unavailable. No values are inferred.

Song et al., ACS Nano (2026) · SI

Formulation components and molecular-weight conversion

SI Table S1 reports 16 screening formulations. Their correspondence to the optimized sW3 formulation and the individual cell and animal experiments is not established in the available sources. Reported molar-ratio coefficients are retained; calculations use their relative proportions.

DMG-PEG2000: 2507 g/mol (catalog average). Component masses below are calculated conversions.

W3-S1-F01 · 35.8:26.9:35.8:1.5

Component mass calculator · W3-S1-F01

Calculated mass conversions; editing inputs creates a research scenario.

ComponentMW (g/mol)Reported molar ratiomg%
W3——
Cholesterol——
DSPC——
DMG-PEG2000——

Not established from the available sources

W3-S1-F02 · 28.1:42.2:28.1:1.5

Component mass calculator · W3-S1-F02

Calculated mass conversions; editing inputs creates a research scenario.

ComponentMW (g/mol)Reported molar ratiomg%
W3——
Cholesterol——
DSPC——
DMG-PEG2000——

Not established from the available sources

W3-S1-F03 · 32.8:49.2:16.4:1.5

Component mass calculator · W3-S1-F03

Calculated mass conversions; editing inputs creates a research scenario.

ComponentMW (g/mol)Reported molar ratiomg%
W3——
Cholesterol——
DSPC——
DMG-PEG2000——

Not established from the available sources

W3-S1-F04 · 38.8:35.8:23.9:1.5

Component mass calculator · W3-S1-F04

Calculated mass conversions; editing inputs creates a research scenario.

ComponentMW (g/mol)Reported molar ratiomg%
W3——
Cholesterol——
DSPC——
DMG-PEG2000——

Not established from the available sources

W3-S1-F05 · 43.8:32.8:21.9:1.5

Component mass calculator · W3-S1-F05

Calculated mass conversions; editing inputs creates a research scenario.

ComponentMW (g/mol)Reported molar ratiomg%
W3——
Cholesterol——
DSPC——
DMG-PEG2000——

Not established from the available sources

W3-S1-F06 · 38.4:16.6:43.5:1.5

Component mass calculator · W3-S1-F06

Calculated mass conversions; editing inputs creates a research scenario.

ComponentMW (g/mol)Reported molar ratiomg%
W3——
Cholesterol——
DSPC——
DMG-PEG2000——

Not established from the available sources

W3-S1-F07 · 47.4:43.7:7.4:1.5

Component mass calculator · W3-S1-F07

Calculated mass conversions; editing inputs creates a research scenario.

ComponentMW (g/mol)Reported molar ratiomg%
W3——
Cholesterol——
DSPC——
DMG-PEG2000——

Not established from the available sources

W3-S1-F08 · 50:38.5:10:1.5

Component mass calculator · W3-S1-F08

Calculated mass conversions; editing inputs creates a research scenario.

ComponentMW (g/mol)Reported molar ratiomg%
W3——
Cholesterol——
DSPC——
DMG-PEG2000——

Not established from the available sources

W3-S1-F09 · 56.3:42.2:0:1.5

Component mass calculator · W3-S1-F09

Calculated mass conversions; editing inputs creates a research scenario.

ComponentMW (g/mol)Reported molar ratiomg%
W3——
Cholesterol——
DSPC——
DMG-PEG2000——

Not established from the available sources

W3-S1-F10 · 65.7:0:32.8:1.5

Component mass calculator · W3-S1-F10

Calculated mass conversions; editing inputs creates a research scenario.

ComponentMW (g/mol)Reported molar ratiomg%
W3——
Cholesterol——
DSPC——
DMG-PEG2000——

Not established from the available sources

W3-S1-F11 · 32.9:56.1:9.5:1.5

Component mass calculator · W3-S1-F11

Calculated mass conversions; editing inputs creates a research scenario.

ComponentMW (g/mol)Reported molar ratiomg%
W3——
Cholesterol——
DSPC——
DMG-PEG2000——

Not established from the available sources

W3-S1-F12 · 57.2:24.8:16.5:1.5

Component mass calculator · W3-S1-F12

Calculated mass conversions; editing inputs creates a research scenario.

ComponentMW (g/mol)Reported molar ratiomg%
W3——
Cholesterol——
DSPC——
DMG-PEG2000——

Not established from the available sources

W3-S1-F13 · 25.7:43.7:29.1:1.5

Component mass calculator · W3-S1-F13

Calculated mass conversions; editing inputs creates a research scenario.

ComponentMW (g/mol)Reported molar ratiomg%
W3——
Cholesterol——
DSPC——
DMG-PEG2000——

Not established from the available sources

W3-S1-F14 · 52.9:13.1:32.5:1.5

Component mass calculator · W3-S1-F14

Calculated mass conversions; editing inputs creates a research scenario.

ComponentMW (g/mol)Reported molar ratiomg%
W3——
Cholesterol——
DSPC——
DMG-PEG2000——

Not established from the available sources

W3-S1-F15 · 70.8:16.6:11.1:1.5

Component mass calculator · W3-S1-F15

Calculated mass conversions; editing inputs creates a research scenario.

ComponentMW (g/mol)Reported molar ratiomg%
W3——
Cholesterol——
DSPC——
DMG-PEG2000——

Not established from the available sources

W3-S1-F16 · 53.7:26.9:17.9:1.5

Component mass calculator · W3-S1-F16

Calculated mass conversions; editing inputs creates a research scenario.

ComponentMW (g/mol)Reported molar ratiomg%
W3——
Cholesterol——
DSPC——
DMG-PEG2000——

Not established from the available sources

Cell performance

Partial evidence; formulation correspondence unresolved

SI Fig. S19: DC2.4 cells were incubated for 24 h with FLuc-mRNA LNPs at 0, 0.1, 1, 2, 5 and 10 µg/mL mRNA. W3 and SM-102 formulations were compared; n=6 biologically independent samples, mean ± SD, one-way ANOVA with Dunnett multiple comparisons. The plotted comparison at 10 µg/mL is marked p<0.05. Exact viability percentages are not transcribed from bar heights. Exact formulation and exposure volume are unresolved.

Song et al., ACS Nano (2026) · SI Fig. S19, p13

Song et al., ACS Nano (2026) · SI Fig. S19, p13

Cell experiment protocol

Partial evidence; formulation correspondence unresolved

Song et al., ACS Nano (2026) · SI Fig. S19, p13

Lipid stocks

The supplied SI does not specify the LNP stock solvent/concentration, aqueous buffer/pH/RNA input concentration, mixing equipment/flow ratio or storage conditions for this experiment. Main-text methods were unavailable. CDCl3 in the NMR section is an analytical solvent and is not used as a formulation solvent.

RNA aqueous phase

The supplied SI does not specify the LNP stock solvent/concentration, aqueous buffer/pH/RNA input concentration, mixing equipment/flow ratio or storage conditions for this experiment. Main-text methods were unavailable. CDCl3 in the NMR section is an analytical solvent and is not used as a formulation solvent.

Mixing and dilution

The supplied SI does not specify the LNP stock solvent/concentration, aqueous buffer/pH/RNA input concentration, mixing equipment/flow ratio or storage conditions for this experiment. Main-text methods were unavailable. CDCl3 in the NMR section is an analytical solvent and is not used as a formulation solvent.

Final treatment / administration

Partial evidence; formulation correspondence unresolved

Incubate DC2.4 cells with FLuc-mRNA LNPs at the reported mRNA concentrations for 24 h and evaluate relative viability against the study controls (SI Fig. S19). Seeding, medium, assay reagent and treatment volume remain unavailable.

Storage and use

The supplied SI does not specify the LNP stock solvent/concentration, aqueous buffer/pH/RNA input concentration, mixing equipment/flow ratio or storage conditions for this experiment. Main-text methods were unavailable. CDCl3 in the NMR section is an analytical solvent and is not used as a formulation solvent.

  1. Incubate DC2.4 cells with FLuc-mRNA LNPs at the reported mRNA concentrations for 24 h and evaluate relative viability against the study controls (SI Fig. S19). Seeding, medium, assay reagent and treatment volume remain unavailable.

Song et al., ACS Nano (2026) · SI Fig. S19, p13

Animal performance

Partial evidence; formulation correspondence unresolved

SI Fig. S25 compares the organ fractions of FLuc expression for screening formulations 1–16; exact fractions, animal strain/sex, dose and sampling time are not fully available from its caption. These are relative expression fractions, not absolute organ delivery.

Song et al., ACS Nano (2026) · SI Fig. S25, p16; Fig. S26e, pp16–17

Song et al., ACS Nano (2026) · SI Fig. S25, p16; Fig. S26e, pp16–17

Animal experiment protocol

Partial evidence; formulation correspondence unresolved

Song et al., ACS Nano (2026) · SI Fig. S25, p16; Fig. S26e, pp16–17

Lipid stocks

The supplied SI does not specify the LNP stock solvent/concentration, aqueous buffer/pH/RNA input concentration, mixing equipment/flow ratio or storage conditions for this experiment. Main-text methods were unavailable. CDCl3 in the NMR section is an analytical solvent and is not used as a formulation solvent.

RNA aqueous phase

The supplied SI does not specify the LNP stock solvent/concentration, aqueous buffer/pH/RNA input concentration, mixing equipment/flow ratio or storage conditions for this experiment. Main-text methods were unavailable. CDCl3 in the NMR section is an analytical solvent and is not used as a formulation solvent.

Mixing and dilution

The supplied SI does not specify the LNP stock solvent/concentration, aqueous buffer/pH/RNA input concentration, mixing equipment/flow ratio or storage conditions for this experiment. Main-text methods were unavailable. CDCl3 in the NMR section is an analytical solvent and is not used as a formulation solvent.

Final treatment / administration

Partial evidence; formulation correspondence unresolved

SI Fig. S25 compares the organ fractions of FLuc expression for screening formulations 1–16; exact fractions, animal strain/sex, dose and sampling time are not fully available from its caption. These are relative expression fractions, not absolute organ delivery.

Storage and use

The supplied SI does not specify the LNP stock solvent/concentration, aqueous buffer/pH/RNA input concentration, mixing equipment/flow ratio or storage conditions for this experiment. Main-text methods were unavailable. CDCl3 in the NMR section is an analytical solvent and is not used as a formulation solvent.

  1. SI Fig. S25 compares the organ fractions of FLuc expression for screening formulations 1–16; exact fractions, animal strain/sex, dose and sampling time are not fully available from its caption. These are relative expression fractions, not absolute organ delivery.

Song et al., ACS Nano (2026) · SI Fig. S25, p16; Fig. S26e, pp16–17

Lipid stocks

The supplied SI does not specify the LNP stock solvent/concentration, aqueous buffer/pH/RNA input concentration, mixing equipment/flow ratio or storage conditions for this experiment. Main-text methods were unavailable. CDCl3 in the NMR section is an analytical solvent and is not used as a formulation solvent.

RNA aqueous phase

The supplied SI does not specify the LNP stock solvent/concentration, aqueous buffer/pH/RNA input concentration, mixing equipment/flow ratio or storage conditions for this experiment. Main-text methods were unavailable. CDCl3 in the NMR section is an analytical solvent and is not used as a formulation solvent.

Mixing and dilution

The supplied SI does not specify the LNP stock solvent/concentration, aqueous buffer/pH/RNA input concentration, mixing equipment/flow ratio or storage conditions for this experiment. Main-text methods were unavailable. CDCl3 in the NMR section is an analytical solvent and is not used as a formulation solvent.

Final treatment / administration

Partial evidence; formulation correspondence unresolved

SI Fig. S26e measures serum cytokines 6 h after intravenous administration (n=3 biologically independent samples, mean ± SD). The available caption does not establish an sW3-versus-W3 cytokine advantage. Broad or clinical safety is not claimed.

Storage and use

The supplied SI does not specify the LNP stock solvent/concentration, aqueous buffer/pH/RNA input concentration, mixing equipment/flow ratio or storage conditions for this experiment. Main-text methods were unavailable. CDCl3 in the NMR section is an analytical solvent and is not used as a formulation solvent.

  1. SI Fig. S26e measures serum cytokines 6 h after intravenous administration (n=3 biologically independent samples, mean ± SD). The available caption does not establish an sW3-versus-W3 cytokine advantage. Broad or clinical safety is not claimed.

Song et al., ACS Nano (2026) · SI Fig. S25, p16; Fig. S26e, pp16–17

Original literature performance figures

Original figures from Song et al., ACS Nano (2026), DOI 10.1021/acsnano.6c17082, supplied Supporting Information. No curves were redrawn. Separate experiment IDs preserve unresolved formulation mapping.

Original SI Fig. S19: DC2.4 viability after 24 h; mRNA concentrations and statistical labels retained.
Original SI Fig. S19: DC2.4 viability after 24 h; mRNA concentrations and statistical labels retained.

Song et al., ACS Nano (2026) · SI Fig. S19, p13

Original SI Fig. S25: relative organ FLuc-expression fractions across screening formulations 1–16; not absolute biodistribution.
Original SI Fig. S25: relative organ FLuc-expression fractions across screening formulations 1–16; not absolute biodistribution.

Song et al., ACS Nano (2026) · SI Fig. S25, p16

Original SI Fig. S26: LPS-primed DC2.4 and RAW264.7 ROS assays (4 h) and serum cytokines (6 h after IV administration). Exact recipes are unresolved.
Original SI Fig. S26: LPS-primed DC2.4 and RAW264.7 ROS assays (4 h) and serum cytokines (6 h after IV administration). Exact recipes are unresolved.

Song et al., ACS Nano (2026) · SI Fig. S26, pp16–17

Song et al., ACS Nano (2026) · SI SI Figs S19/S25/S26

Main article PDF is still required for full pKa, N/P, formulation-to-performance mapping and complete preparation/cell/animal methods. Supporting Information has already been received.